VIP PEPTIDE
Also known as
VIP PEPTIDE is catalogued in the Peptides Pub research index, with coverage focused on Cognition & mood.
Evidence
Animal or in-vitro only
Risk band
Known AEs, monitoring advised
Research goals
Summary
Vasoactive intestinal peptide (VIP) is an endogenous gut and neuroendocrine signalling peptide, first characterized as a candidate gut hormone and closely related to PACAP and PHI, with which it shares precursor processing and tissue distribution [1,2]. The large literature associated with VIP reflects its role as a native hormone and disease target (including VIP-producing tumors) rather than an established administered therapeutic [1]. Reviews note bioactive peptides including VIP-related molecules are being explored for neurological disorders, but this remains investigational [3]. The most concrete pharmacology in the provided papers concerns a VIP receptor antagonist peptide (ANT308) chemically modified and tested in leukemic mice, which is preclinical and targets the receptor rather than administering VIP as a drug [4]. The provided sources contain no human interventional randomized controlled trials of administering VIP therapeutically, so clinical evidence for VIP as a therapeutic is preliminary.
Sources
- 1. VIP and PACAP Results and problems in cell differentiation, 2010.
- 2. Candidate hormones of the gut. V. Vasoactive intestinal peptide (VIP) Gastroenterology, 1974.
- 3. Peptide Based Therapy for Neurological Disorders Current protein & peptide science, 2021.
- 4. Chemical Modifications to Enhance the Drug Properties of a VIP Receptor Antagonist (ANT) Peptide International journal of molecular sciences, 2024.
For educational purposes only.